A judge on Wednesday awarded the state of Arkansas $1.2 billion following a Tuesday jury verdict against Johnson & Johnson over the marketing of the anti-psychotic drug Risperdal. Houston firm Bailey Perrin Bailey, which represented Arkansas, stands to receive a 15 percent contingency fee, or nearly $180.9 million.
Johnson & Johnson Hit with $1.2 Billion Judgment in Arkansas Risperdal Case
The American Lawyer
April 12, 2012